HPLC法测定复脉灵胶囊中盐酸麻黄碱及盐酸伪麻黄碱含量

摘 要 目的:建立复脉灵胶囊中盐酸麻黄碱、盐酸伪麻黄碱的含量测定方法。方法: 采用HPLC法,流动相: 乙腈-水-磷酸-三乙胺（３∶97∶0.1∶0.1）;色谱柱：Aglient TC-C₁₈（250 mm×4.6 mm,5 μm）;检测波长：205 nm;流速：1.2 ml·min^-1;柱温：室温。结果:盐酸麻黄碱的进样量在0.187～0.937 μg范围内具有良好的线性关系（r=0.999 7）,平均回收率为99.26%,RSD为2.70%（n=6）;盐酸伪麻黄碱的进样量在0.226～1.130 μg范围内具有良好的线性关系（r=0.999 7）,平均回收率为98.77%,RSD为2.21%（n=6）。结论:该方法操作简便、灵敏度高、结果准确,可作为复脉灵胶囊中盐酸麻黄碱、盐酸伪麻黄碱的含量测定方法。     

HPLC法同时测定桂灵片中6种生物碱的含量

目的：建立HPLC法同时测定桂灵片中6种生物碱的含量。方法：采用Agilent Eclipse Plus-C18色谱柱（4.6 mm×250 mm,4.6 μm）,以乙腈（A）-0.1%磷酸（B）为流动相,梯度洗脱,流速1.0 mL·min-1,测定波长：吗啡、盐酸麻黄碱、盐酸伪麻黄碱、盐酸甲基麻黄碱、磷酸可待因210 nm;盐酸罂粟碱251 nm。结果：吗啡、盐酸麻黄碱、盐酸伪麻黄碱、盐酸甲基麻黄碱、磷酸可待因和盐酸罂粟碱进样量分别在0.001 3～0.13 μg（r=0.999 9）,0.002 5～0.25 μg（r=0.999 9）,0.002 5～0.25 μg（r=0.999 9）,0.005 4～0.27 μg（r=0.999 9）,0.002 6～0.26 μg（r=0.999 9）,0.000 5～0.11 μg（r=0.999 9）范围内呈良好线性关系,平均回收率（n=6）分别为101.6%、100.2%、95.3%、99.2%、103.5%、100.2%。结论：该方法可以用于桂灵片的质量控制。     

HPLC法测定麻黄止嗽丸中盐酸麻黄碱及盐酸伪麻黄碱的含量

摘 要 目的: 建立麻黄止嗽丸中盐酸麻黄碱及盐酸伪麻黄碱含量的测定方法。方法: 采用反相高效液相色谱法,色谱柱为Kromasil C₁₈柱(200 mm×4.6 mm,5 μm),流动相为乙腈 0.1％磷酸溶液（含0.1%三乙胺）（4∶96）,流速为1 ml·min^-1,检测波长为207 nm,柱温：室温,进样量：5 μl。结果:盐酸麻黄碱在0.02～0.52 μg 范围内线性关系良好(r=0.999 9),平均回收率为97.8%,RSD为1.6%(n=6);盐酸伪麻黄碱在0.02～0.51 μg范围内线性关系良好(r=0.999 8),平均回收率为99.4%,RSD为0.9%(n=6)。结论:该方法准确可靠,可用于麻黄止嗽丸中盐酸麻黄碱和盐酸伪麻黄碱的含量测定。     

固相萃取高效液相法测定复方川贝精胶囊中3种麻黄碱成分的含量

摘要：目的:建立同时测定复方川贝精胶囊中盐酸麻黄碱、盐酸伪麻黄碱和盐酸甲基麻黄碱含量的方法。方法:采用固相萃取高效液相色谱法,色谱柱为Phenomenex Luna C18（2）柱（150 mm×4.60 mm,5μm）,流动相为乙腈-0.1%磷酸溶液（2∶98）,检测波长为210 nm,流速为1.0 ml·min-1,柱温为25℃。结果:盐酸麻黄碱、盐酸伪麻黄碱和盐酸甲基麻黄碱的浓度分别在2.0～128.0,0.8～51.2,0.4～9.0μg·ml-1范围内与各自色谱峰面积呈良好线性关系（r=1.000 0）;盐酸麻黄碱、盐酸伪麻黄碱和盐酸甲基麻黄碱的平均加样回收率分别为98.90%（RSD=0.51%）、98.49%（RSD=0.87%）、97.50%（RSD=1.15%）（n=6）。结论:该方法简便、快速、准确,专属性、重复性良好,可用于复方川贝精胶囊的质量控制。     

HPLC法同时测定防风通圣颗粒中6种成分的含量

摘要：目的:建立采用HPLC法同时测定防风通圣颗粒中盐酸麻黄碱、盐酸伪麻黄碱、栀子苷、黄芩苷、汉黄芩苷、甘草酸含量的方法。方法:采用Welch Ultimate Phenyl-Ether色谱柱（250 mm×4.6 mm,5μm）;流动相为乙腈-0.2%磷酸（含0.1%NH4Cl）,梯度洗脱;流速为1.0 ml·min-1;柱温为30℃;检测波长分别为210 nm（盐酸麻黄碱、盐酸伪麻黄碱）、238 nm（栀子苷）、278 nm（黄芩苷、汉黄芩苷）、252 nm（甘草酸）;进样量10μl。结果:盐酸麻黄碱、盐酸伪麻黄碱、栀子苷、黄芩苷、汉黄芩苷、甘草酸分别在2.07～20.67μg·ml-1（r=0.999 6）、1.14～11.37μg·ml-1（r=0.999 4）、3.13～31.33μg·ml-1（r=0.999 7）、20.73～207.30μg·ml-1（r=0.999 9）、4.95～49.55μg·ml-1（r=0.999 8）、7.98～79.76μg·ml-1（r=0.999 9）范围内呈良好的线性关系;6种成分加样回收率的平均值分别为98.79%、98.12%、99.24%、102.26%、96.66%、100.57%,RSD分别为2.42%、2.12%、2.47%、2.36%、2.34%、1.93%（n=6）。结论:所建立的方法准确、重复性好,可用于防风通圣颗粒中6种成分的同时测定,并为质量控制体系的完善提供依据。     

HPLC法测定麻黄水煎液中盐酸麻黄碱和盐酸伪麻黄碱的含量

目的:建立高效液相色谱法测定麻黄水煎液中盐酸麻黄碱和盐酸伪麻黄碱的含量。方法:采用Diamonsil C₁₈柱（250mm×4.6 mm,5μm）,以甲醇-0.5%SDS-磷酸-三乙胺（60:40:1.25:1）为流动相,流速为1.0 ml·min^-1,检测波长为210 nm。结果:盐酸麻黄碱和盐酸伪麻黄碱浓度分别在16.00～64.00μg·ml^-1（r=0.999 4）和3.86～15.42μg·ml^-1（r=0.999 1）范围内呈现良好的线性关系,平均加样回收率分别为99.15%和101.30%,RSD分别为2.09%和1.55%（n=9）。结论:该方法可靠、准确、重复性好,可用于麻黄水煎液中盐酸麻黄碱和盐酸伪麻黄碱的含量测定。     

HPLC测定万通筋骨片中盐酸麻黄碱和盐酸伪麻黄碱的含量

目的 建立测定万通筋骨片中盐酸麻黄碱和盐酸伪麻黄碱的分析方法.方法 采用Thermo Syncronis C18色谱柱(250mm×4.6mm,5μm),以乙腈-0.05mol·L-1磷酸二氢钾溶液(用磷酸调节pH =3.0)(5∶95)为流动相,等度洗脱,体积流量1.0mL· min-1,柱温30℃;检测波长210nm.结果 盐酸麻黄碱和盐酸伪麻黄碱进样量分别在0.04578～0.9156μg(r=1)和0.02144～0.4288 μg(r=0.9999)范围内线性关系良好,平均加样回收率(n=6)分别为95.6％,97.6％,RSD分别为0.93％,0.80％.结论 本实验为万通筋骨片质量评价提供了简单、有效的方法.     

HPLC法测定乙肝扶正胶囊中盐酸麻黄碱和盐酸伪麻黄碱的含量

目的：建立测定乙肝扶正胶囊中盐酸麻黄碱和盐酸伪麻黄碱的含量的高效液相色谱法,制定含量参考限度。方法: 考察了三种不同的色谱柱,分别为色谱柱1：Agilent ZORBAX SB-C18(4.6mm×250mm,5.0μm),柱2：Agilent Eclipse Plus C18(4.6mm×250 mm,5.0μm),柱3：SHARPSIL-T C18(4.6mm×250 mm,5μm);流动相：乙腈-0.2%磷酸（4:96）;检测波长：206nm,流速1.0mL?min-1,柱温：30℃。结果：盐酸麻黄碱在13~131 μg?mL-1的范围内呈良好的线性关系,回归方程为Y＝22.6143X+3.2897,r为1.0000,方法平均回收率103.7%（RSD3.16%, n=6）,84批样品的盐酸麻黄碱含量在0.05~0.28mg?g-1之间;盐酸伪麻黄碱在9~87 μg?mL-1的范围内呈良好的线性关系,回归方程为Y＝23.3020X+1.1772,r为1.0000,方法平均回收率95.4%（RSD1.11%, n=6）,84批样品的盐酸伪麻黄碱含量在0.02~0.12 mg?g-1之间。结论：该方法简便,快速,准确,可用于该制剂中盐酸麻黄碱和盐酸伪麻黄碱的含量测定,测定了84批次样品的数据,拟定了含量参考限度值。     

反相-高效液相色谱法测定黄龙止咳颗粒中盐酸麻黄碱和盐酸伪麻黄碱的含量

目的：建立反相-高效液相色谱法（RP-HPLC）测定黄龙止咳颗粒中盐酸麻黄碱和盐酸伪麻黄碱含量的方法.方法：色谱柱：AgilentZORBAXSB-C18色谱柱（4.6mm×250mm,5μm）;流动相：乙腈-磷酸二氢钾溶液（4∶96）（取磷酸二氢钾6.8g,加水1000ml溶解后,加三乙胺1ml,用磷酸调节pH值至3.0）;检测波长：210nm;柱温：35℃.结果：盐酸麻黄碱、盐酸伪麻黄碱进样量分别在0.0040～0.0480μg（r=0.9996）、0.0237～0.2844μg（r=0.9999）范围内线性关系良好;平均回收率分别为96.2％、97.5％,RSD分别为1.97％、1.81％.结论：本方法简便、准确,适用于黄龙止咳颗粒中盐酸麻黄碱和盐酸伪麻黄碱的含量测定.     

HPLC法测定麻杏抗感颗粒中盐酸麻黄碱和盐酸伪麻黄碱的含量

目的 建立麻杏抗感颗粒中盐酸麻黄碱和盐酸伪麻黄碱的含量测定方法。方法 采用高效液相色谱（HPLC）法,色谱柱：Wondasil C₁₈（4.6 mm×250 mm,5 μm）;流动相：乙腈-0.1%磷酸溶液（5：95）;流速：1 ml/min;检测波长：215 nm;柱温：30℃;进样量：10 μl。结果 盐酸麻黄碱、盐酸伪麻黄碱的质量浓度分别在4.231~42.31 μg/ml（r=0.999 7）、1.187~11.87 μg/ml（r=0.999 9）范围内与各自峰面积线性关系良好,平均加样回收率为分别为98.9%、98.1%;RSD分别为0.48%、0.64%。结论 该法准确度高、重复性好, 可用于麻杏抗感颗粒中盐酸麻黄碱和盐酸伪麻黄碱的含量测定。     

维拉佐酮盐酸盐

由Trovis Pharma LLC制药公司研制的维拉佐酮盐酸盐(vilazodone hydrochloride)于2011年1月21日由FDA批准上市,商品名为Viibryd,用于治疗成年人重度抑郁症(major depressive disorder,MDD)[1]。Viibryd将以10 mg、20 mg和40 mg片剂上市。     

Levalbuterol hydrochloride

Racemic salbutamol (racemic albuterol) ameliorates symptoms of asthma by activating b-adrenoceptors on nerve, smooth muscle and inflammatory cells within the airways. Racemic salbutamol comprises equal proportions of 2 isomers: (S)-salbutamol and (R)-salbutamol, with the latter being exclusively responsible for activation of b-adrenoceptors. Accordingly, within racemic salbutamol it is (R)-salbutamol that efficiently relieves obstruction of asthmatic airways and affords highly effective protection from bronchoconstrictor stimuli, including allergens. During regular use of racemic salbutamol, there is a progressive decline of protective efficacy and a corresponding intensification of airway responsiveness. This decline is largely absent during regular use of (R)-salbutamol. Consequently, bronchodilator responses to sub-maximal doses of (R)-salbutamol exceed responses to the equivalent dose of (R)-salbutamol given as the racemate. For example, in asthmatics with baseline FEVs ≤ 60%, 1.25 mg of nebulised (R)-salbutamol achieved a maximal 52% change in FEV while 2.5 mg of racemic salbutamol only achieved a 38% change in FEV. Since extrapulmonary effects (e.g., tremor, heart rate) of b agonists are related to dose and limit the use of b agonist therapy, (R)-salbutamol at 0.63 mg provides uncompromised efficacy with marked reduction of side-effects. In addition to quantitative differences, the constituent isomers of salbutamol also exhibit qualitative differences. Thus, (R)-salbutamol inhibits activation of human eosinophils in vitro whereas, under the same conditions and concentrations, (S)-salbutamol augments activation of these cells. This property of (S)-salbutamol may explain why eosinophilia in induced sputum from subjects with allergic asthma is increased by regular use of racemic salbutamol. Similarly, the capacity of (R)-salbutamol to suppress hyperresponsiveness of the airways can be contrasted with the capacity of (S)-salbutamol to intensify hyperresponsiveness. This action of (S)-salbutamol would explain why regular use of racemic salbutamol intensifies the bronchoconstrictor response to antigen in subjects with allergic asthma. Taken together, these findings imply that replacement of racemic salbutamol by (R)-salbutamol will diminish, or even eliminate, the anomalous actions that have curtailed the efficacy of racemic salbutamol. Pharmacokinetically, (R)-salbutamol exhibits near absolute conformational stability (i.e., no conversion to (S)-salbutamol). If in vitro anti-inflammatory actions of (R)-salbutamol are also manifest in asthmatic airways, (R)-salbutamol could provide a novel approach to asthma therapy which combines bronchodilation and bronchoprotection with anti-inflammatory efficacy.     

Phenylpropanolamine hydrochloride

Phenylpropanolamine has been classified by the FDA advisory review panel as generally safe and effective for short-term weight control. The maximum daily dose for this indication is 75 mg. When used in recommended doses by patients without significant risk factors, serious side effects appear to occur infrequently. The pharmacist has an important role in preventing misuse and abuse of phenylpropanolamine through counseling the patient about its appropriate, short-term (not exceeding 12 weeks) use in a comprehensive weight-reduction program. Patients should be alerted to signs and symptoms of serious adverse reactions and advised to discontinue use if any reactions appear.     

Ponatinib hydrochloride

2012年12月14日,FDA批准ponatinib hydrochloride(商品名为Iclusig)在美国上市,该药由Ariad制药公司开发,该药为片剂,用于慢性髓细胞白血病(CML)和费城染色体阳性急性淋巴细胞白血病(Ph+ALL)的治疗。Ponatinib hydrochloride的中文名称:3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-4-甲基-N-{4-[(4-甲基哌嗪-1-基)甲基]-     

Levalbuterol hydrochloride

Racemic salbutamol (racemic albuterol) ameliorates symptoms of asthma by activating beta-adrenoceptors on nerve, smooth muscle and inflammatory cells within the airways. Racemic salbutamol comprises equal proportions of 2 isomers: (S)-salbutamol and (R)-salbutamol, with the latter being exclusively responsible for activation of beta-adrenoceptors. Accordingly, within racemic salbutamol it is (R)-salbutamol that efficiently relieves obstruction of asthmatic airways and affords highly effective protection from bronchoconstrictor stimuli, including allergens. During regular use of racemic salbutamol, there is a progressive decline of protective efficacy and a corresponding intensification of airway responsiveness. This decline is largely absent during regular use of (R)-salbutamol. Consequently, bronchodilator responses to sub-maximal doses of (R)-salbutamol exceed responses to the equivalent dose of (R)-salbutamol given as the racemate. For example, in asthmatics with baseline FEVs 相似文献